Anti-GRID2IP monoclonal antibody
Pre-made anti-GRID2IP monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to GRID2IP/GRID2IP products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP2532-Ab-1/ GM-Tg-hg-IP2532-Ab-2 | Anti-Human GRID2IP monoclonal antibody | Human |
GM-Tg-rg-IP2532-Ab-1/ GM-Tg-rg-IP2532-Ab-2 | Anti-Rat GRID2IP monoclonal antibody | Rat |
GM-Tg-mg-IP2532-Ab-1/ GM-Tg-mg-IP2532-Ab-2 | Anti-Mouse GRID2IP monoclonal antibody | Mouse |
GM-Tg-cynog-IP2532-Ab-1/ GM-Tg-cynog-IP2532-Ab-2 | Anti-Cynomolgus/ Rhesus macaque GRID2IP monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP2532-Ab-1/ GM-Tg-felg-IP2532-Ab-2 | Anti-Feline GRID2IP monoclonal antibody | Feline |
GM-Tg-cang-IP2532-Ab-1/ GM-Tg-cang-IP2532-Ab-2 | Anti-Canine GRID2IP monoclonal antibody | Canine |
GM-Tg-bovg-IP2532-Ab-1/ GM-Tg-bovg-IP2532-Ab-2 | Anti-Bovine GRID2IP monoclonal antibody | Bovine |
GM-Tg-equg-IP2532-Ab-1/ GM-Tg-equg-IP2532-Ab-2 | Anti-Equine GRID2IP monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP2532-Ab-1/ GM-Tg-hg-IP2532-Ab-2; GM-Tg-rg-IP2532-Ab-1/ GM-Tg-rg-IP2532-Ab-2; GM-Tg-mg-IP2532-Ab-1/ GM-Tg-mg-IP2532-Ab-2; GM-Tg-cynog-IP2532-Ab-1/ GM-Tg-cynog-IP2532-Ab-2; GM-Tg-felg-IP2532-Ab-1/ GM-Tg-felg-IP2532-Ab-2; GM-Tg-cang-IP2532-Ab-1/ GM-Tg-cang-IP2532-Ab-2; GM-Tg-bovg-IP2532-Ab-1/ GM-Tg-bovg-IP2532-Ab-2; GM-Tg-equg-IP2532-Ab-1/ GM-Tg-equg-IP2532-Ab-2 |
Products Name | Anti-GRID2IP monoclonal antibody |
Format | mab |
Target Name | GRID2IP |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-GRID2IP monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP2532-Ag-1 | Recombinant multi-species GRD2I/ GRID2IP/ DELPHILIN protein |
Target information
Target ID | GM-IP2532 |
Target Name | GRID2IP |
Gene ID | 392862,170935,288484,704557,609131,101100528,518088,100061666 |
Gene Symbol and Synonyms | DELPHILIN,GRID2IP |
Uniprot Accession | A4D2P6 |
Uniprot Entry Name | GRD2I_HUMAN |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000215045 |
Target Classification | N/A |
The target: GRID2IP, gene name: GRID2IP, also named as DELPHILIN. Glutamate receptor delta-2 (GRID2; MIM 602368) is predominantly expressed at parallel fiber-Purkinje cell postsynapses and plays crucial roles in synaptogenesis and synaptic plasticity. GRID2IP1 interacts with GRID2 and may control GRID2 signaling in Purkinje cells (Matsuda et al., 2006 [PubMed 16835239]).[supplied by OMIM, Mar 2008].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.